US6878728B1
(en)
|
1999-06-11 |
2005-04-12 |
Vertex Pharmaceutical Incorporated |
Inhibitors of aspartyl protease
|
US20040122000A1
(en)
*
|
1981-01-07 |
2004-06-24 |
Vertex Pharmaceuticals Incorporated. |
Inhibitors of aspartyl protease
|
US5614533A
(en)
*
|
1987-03-13 |
1997-03-25 |
Bio-Mega/Boehringer Ingelheim Research, Inc. |
Substituted pipecolinic acid derivatives as HIV protease inhibitors
|
USH1649H
(en)
|
1987-07-31 |
1997-05-06 |
Barrish; Joel C. |
HIV protease inhibitor combinations
|
CA1340588C
(en)
*
|
1988-06-13 |
1999-06-08 |
Balraj Krishan Handa |
Amino acid derivatives
|
GB8927915D0
(en)
*
|
1989-12-11 |
1990-02-14 |
Hoffmann La Roche |
Novel alcohols
|
US5430041A
(en)
*
|
1991-05-10 |
1995-07-04 |
Hoffmann-La Roche Inc. |
Amino acid derivatives having antiviral activity
|
CN1071930A
(zh)
*
|
1991-07-10 |
1993-05-12 |
伊莱利利公司 |
用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
|
US5508407A
(en)
*
|
1991-07-10 |
1996-04-16 |
Eli Lilly And Company |
Retroviral protease inhibitors
|
WO1993008184A1
(en)
*
|
1991-10-23 |
1993-04-29 |
Merck & Co., Inc. |
Hiv protease inhibitors
|
US5413999A
(en)
*
|
1991-11-08 |
1995-05-09 |
Merck & Co., Inc. |
HIV protease inhibitors useful for the treatment of AIDS
|
CA2081970C
(en)
*
|
1991-11-08 |
1997-07-08 |
Joseph P. Vacca |
Hiv protease inhibitors useful for the treatment of aids
|
US5888992A
(en)
|
1992-03-11 |
1999-03-30 |
Narhex Limited |
Polar substituted hydrocarbons
|
US6071895A
(en)
|
1992-03-11 |
2000-06-06 |
Narhex Limited |
Polar-substituted hydrocarbons
|
BR9306058A
(pt)
|
1992-03-11 |
1997-11-18 |
Narhex Ltd |
Derivados de amina de hidrocarbonetos oxo- e hidroxi- substituidos
|
ATE116640T1
(de)
*
|
1992-03-13 |
1995-01-15 |
Bio Mega Boehringer Ingelheim |
Substituierte pipecoline-säurederivate als hiv- protease-hemmer.
|
JPH07508020A
(ja)
*
|
1992-05-21 |
1995-09-07 |
ジー.ディー.サール アンド カンパニー |
レトロウイルスプロテアーゼインヒビター
|
US5559256A
(en)
*
|
1992-07-20 |
1996-09-24 |
E. R. Squibb & Sons, Inc. |
Aminediol protease inhibitors
|
DK0656887T3
(da)
|
1992-08-25 |
1999-07-05 |
Searle & Co |
Hydroxyethylaminosulfonamider til anvendelse som inhibitorer af retrovirale proteaser
|
US5723490A
(en)
*
|
1992-09-08 |
1998-03-03 |
Vertex Pharmaceuticals Incorporated |
THF-containing sulfonamide inhibitors of aspartyl protease
|
IS2334B
(is)
*
|
1992-09-08 |
2008-02-15 |
Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) |
Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
|
US5783701A
(en)
|
1992-09-08 |
1998-07-21 |
Vertex Pharmaceuticals, Incorporated |
Sulfonamide inhibitors of aspartyl protease
|
TW372972B
(en)
*
|
1992-10-23 |
1999-11-01 |
Novartis Ag |
Antiretroviral acyl compounds
|
US5380849A
(en)
*
|
1992-11-09 |
1995-01-10 |
Merck & Co., Inc. |
Process for optically pure decahydroisoqiunolines
|
US5430150A
(en)
*
|
1992-12-16 |
1995-07-04 |
American Cyanamid Company |
Retroviral protease inhibitors
|
US5434265A
(en)
*
|
1992-12-22 |
1995-07-18 |
Eli Lilly And Company |
Inhibitors of HIV protease
|
US5484926A
(en)
|
1993-10-07 |
1996-01-16 |
Agouron Pharmaceuticals, Inc. |
HIV protease inhibitors
|
US5846993A
(en)
*
|
1992-12-22 |
1998-12-08 |
Agouron Pharmaceuticals, Inc. |
HIV protease inhibitors
|
US5733906A
(en)
*
|
1993-10-12 |
1998-03-31 |
Eli Lilly And Company |
Inhibitors of HIV Protease useful for the treatment of Aids
|
MX9308016A
(es)
*
|
1992-12-22 |
1994-08-31 |
Lilly Co Eli |
Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
|
US5491166A
(en)
*
|
1992-12-22 |
1996-02-13 |
Eli Lilly And Company |
Inhibitors of HIV protease useful for the treatment of AIDS
|
MX9308025A
(es)
*
|
1992-12-22 |
1994-08-31 |
Lilly Co Eli |
Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
|
WO1994017096A1
(en)
*
|
1993-01-17 |
1994-08-04 |
Schering Corporation |
Peptides having anti-hiv activity
|
US5939430A
(en)
*
|
1993-02-22 |
1999-08-17 |
Merrell Pharmaceuticals Inc. |
Combinations of retroviral inhibitors
|
US5455353A
(en)
*
|
1993-03-24 |
1995-10-03 |
Hoffmann-La Roche Inc. |
4-(benzyl-2-oxo-oxazolidin-5 ylmethyl)N tertbutyl-decahydroisoquinoline-3-carboxamides
|
ES2098080T3
(es)
*
|
1993-07-15 |
1997-04-16 |
Hoffmann La Roche |
Procedimiento para la obtencion de un derivado de n-tert-butilisoquinolin-3-carboxamida y compuestos intermedios de este procedimiento.
|
HUT74685A
(en)
*
|
1994-02-02 |
1997-01-28 |
Lilly Co Eli |
Hiv protease inhibitors and intermediates piperidine derivatives condensed with heterocycles as intermediates for hiv protease inhibitors
|
ES2139195T3
(es)
*
|
1994-03-07 |
2000-02-01 |
Vertex Pharma |
Derivados de sulfonamidas como inhibidores de la aspartil-proteasa.
|
US5527829A
(en)
*
|
1994-05-23 |
1996-06-18 |
Agouron Pharmaceuticals, Inc. |
HIV protease inhibitors
|
US5470979A
(en)
*
|
1994-07-01 |
1995-11-28 |
American Cyanamid Company |
Asymmetric synthesis of bicyclic amino acid esters
|
US5523463A
(en)
*
|
1994-09-23 |
1996-06-04 |
Hoffmann-La Roche Inc. |
Method of producing halogenated and alpha-aminoalchohols
|
US5591885A
(en)
*
|
1994-09-23 |
1997-01-07 |
Hoffman-La Roche Inc. |
Process for the preparation of halogenated α-aminoketone compounds
|
US5691372A
(en)
*
|
1995-04-19 |
1997-11-25 |
Vertex Pharmaceuticals Incorporated |
Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
|
US6008228A
(en)
*
|
1995-06-06 |
1999-12-28 |
Hoffman-La Roche Inc. |
Pharmaceutical compositions containing proteinase inhibitors
|
JP3238412B2
(ja)
*
|
1995-06-06 |
2001-12-17 |
エフ・ホフマン−ラ ロシュ アーゲー |
プロテイナーゼインヒビター及びモノグリセリドを含む医薬組成物
|
US6004957A
(en)
*
|
1995-06-07 |
1999-12-21 |
Vertex Pharmaceuticals, Incorporated |
Sulfonamide inhibitors of aspartyl protease
|
AU759386B2
(en)
*
|
1995-06-29 |
2003-04-10 |
Abbvie Inc. |
Use of Ritonavir (ABT-538) for improving the pharmacokinetics of drugs metabolized by cytochrome P450 in a method of treating AIDS
|
US6037157A
(en)
|
1995-06-29 |
2000-03-14 |
Abbott Laboratories |
Method for improving pharmacokinetics
|
AU7508196A
(en)
|
1995-11-13 |
1997-06-05 |
Gerard Voerman |
Anti-viral isolates obtainable from leeches
|
US5914332A
(en)
|
1995-12-13 |
1999-06-22 |
Abbott Laboratories |
Retroviral protease inhibiting compounds
|
US5883252A
(en)
*
|
1996-01-26 |
1999-03-16 |
Vertex Pharmaceuticals Incorporated |
Aspartyl protease inhibitors
|
US5587481A
(en)
*
|
1996-02-20 |
1996-12-24 |
The Monsanto Company |
Preparation of (S)-decahydroisoquinoline-3-carboxylic acid t-butylamide
|
US5914404A
(en)
*
|
1996-08-09 |
1999-06-22 |
Hoffmann-La Roche Inc. |
Process for the preparation of quinargine
|
EP0823424A1
(de)
*
|
1996-08-09 |
1998-02-11 |
F. Hoffmann-La Roche Ag |
Verfahren zur Herstellung von Chinargin
|
US5925759A
(en)
|
1996-09-05 |
1999-07-20 |
Agouron Pharmaceuticals, Inc. |
Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
|
US5962725A
(en)
|
1996-09-05 |
1999-10-05 |
Agouron Pharmaceuticals, Inc. |
Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
|
US5705647A
(en)
*
|
1996-09-05 |
1998-01-06 |
Agouron Pharmaceuticals, Inc. |
Intermediates for making HIV-protease inhibitors
|
US6232333B1
(en)
|
1996-11-21 |
2001-05-15 |
Abbott Laboratories |
Pharmaceutical composition
|
DE59709770D1
(de)
|
1996-12-11 |
2003-05-15 |
Hoffmann La Roche |
Verfahren zur Herstellung gemischter Anhydride
|
US6001851A
(en)
*
|
1997-03-13 |
1999-12-14 |
Agouron Pharmaceuticals, Inc. |
HIV protease inhibitors
|
US6084107A
(en)
*
|
1997-09-05 |
2000-07-04 |
Agouron Pharmaceuticals, Inc. |
Intermediates for making HIV-protease inhibitors
|
US6143742A
(en)
*
|
1997-12-11 |
2000-11-07 |
Fuisz Technologies Ltd |
Treatment for necrotizing infections
|
US6436989B1
(en)
|
1997-12-24 |
2002-08-20 |
Vertex Pharmaceuticals, Incorporated |
Prodrugs of aspartyl protease inhibitors
|
FR2779653B1
(fr)
*
|
1998-06-11 |
2002-12-20 |
Inst Nat Sante Rech Med |
Utilisation de composes modulateurs du proteasome en therapie
|
AP1717A
(en)
*
|
1998-06-19 |
2007-01-30 |
Vertex Pharma |
Sulfonamide inhibitors of aspartyl protease.
|
KR100277723B1
(ko)
|
1998-12-14 |
2001-01-15 |
남창우 |
광학적으로 순수한 데카하이드로이소퀴놀린카르복사미드의 연속제조공정
|
US7635690B2
(en)
*
|
1999-01-22 |
2009-12-22 |
Emory University |
HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
|
US7115584B2
(en)
*
|
1999-01-22 |
2006-10-03 |
Emory University |
HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
|
US6765019B1
(en)
*
|
1999-05-06 |
2004-07-20 |
University Of Kentucky Research Foundation |
Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
|
EP1733725B2
(en)
*
|
1999-06-04 |
2012-08-08 |
Abbott Laboratories |
Pharmaceutical solution comprising ritonavir, a solvent (long chain fatty acid) and water
|
CA2375954A1
(en)
*
|
1999-07-20 |
2001-01-25 |
Mark Charest |
Alpha-hydroxy-gamma-¬¬(carbocyclic-or heterocyclic-substituted)amino|carbonyl|alkanamide derivatives and uses thereof
|
US6589962B1
(en)
|
1999-07-20 |
2003-07-08 |
Merck & Co., Inc. |
Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
|
ATE377011T1
(de)
|
1999-11-24 |
2007-11-15 |
Merck & Co Inc |
Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1- piperazinpentanamide als hiv-proteasehemmer
|
IT1313682B1
(it)
*
|
1999-11-25 |
2002-09-09 |
Archimica Spa |
Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
|
SI1248600T1
(sl)
|
2000-01-19 |
2008-08-31 |
Abbott Lab |
Izboljšane farmacevtske formulacije inhibitorjev proteaze HIV
|
US6448245B1
(en)
|
2000-05-04 |
2002-09-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Methods of and compounds for inhibiting calpains
|
IT1318986B1
(it)
*
|
2000-10-09 |
2003-09-19 |
Archimica S P A Ora Clariant L |
Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
|
GB0028483D0
(en)
|
2000-11-22 |
2001-01-10 |
Hoffmann La Roche |
Hydroxyethylamine HIV protease inhibitors
|
US20030191121A1
(en)
*
|
2001-08-09 |
2003-10-09 |
Miller Ross A. |
Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation
|
EP1463807A4
(en)
|
2001-12-19 |
2006-04-12 |
Bristol Myers Squibb Co |
FORMATHYDROGENASE FROM PICHIA PASTORIS AND USES THEREOF
|
US20040067216A1
(en)
*
|
2002-02-22 |
2004-04-08 |
Karki Shyam B. |
Hiv protease inhibitors supported on cation exchange resins for oral administration
|
EP2316468A1
(en)
|
2002-02-22 |
2011-05-04 |
Shire LLC |
Delivery system and methods for protecting and administering dextroamphetamine
|
US7157489B2
(en)
*
|
2002-03-12 |
2007-01-02 |
The Board Of Trustees Of The University Of Illinois |
HIV protease inhibitors
|
US7132568B2
(en)
*
|
2002-06-17 |
2006-11-07 |
Sunesis Pharmaceuticals, Inc. |
Aspartyl protease inhibitors
|
US7115652B2
(en)
*
|
2002-06-17 |
2006-10-03 |
Sunesis Pharmaceuticals, Inc. |
Aspartyl protease inhibitors
|
JP4608488B2
(ja)
*
|
2003-07-11 |
2011-01-12 |
エフ.ホフマン−ラ ロシュ アーゲー |
メシル酸サキナビル経口投与剤型
|
EP1604662A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft |
1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus
|
ATE505196T1
(de)
|
2004-07-27 |
2011-04-15 |
Gilead Sciences Inc |
Nukleosid phosphonat konjugate als anti hiv mittel
|
WO2006134612A1
(en)
*
|
2005-06-16 |
2006-12-21 |
Hetero Drugs Limited |
A process for the preparation of saquinavir using novel intermediate
|
WO2008112289A2
(en)
|
2007-03-12 |
2008-09-18 |
Nektar Therapeutics |
Oligomer-protease inhibitor conjugates
|
TW200914011A
(en)
*
|
2007-06-29 |
2009-04-01 |
Gilead Sciences Inc |
Therapeutic compositions and methods
|
KR20100028656A
(ko)
*
|
2007-06-29 |
2010-03-12 |
길리애드 사이언시즈, 인코포레이티드 |
치료 조성물 및 그의 용도
|
US20100093811A1
(en)
*
|
2007-09-25 |
2010-04-15 |
Coburn Craig A |
Hiv protease inhibitors
|
US9095620B2
(en)
*
|
2008-03-12 |
2015-08-04 |
Nektar Therapeutics |
Reagents
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
CN102272134B
(zh)
|
2008-12-09 |
2013-10-16 |
吉里德科学公司 |
Toll样受体调节剂
|
US8551973B2
(en)
*
|
2008-12-23 |
2013-10-08 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
EP3222628A1
(en)
*
|
2008-12-23 |
2017-09-27 |
Gilead Pharmasset LLC |
Nucleoside phosphoramidates
|
US8716263B2
(en)
|
2008-12-23 |
2014-05-06 |
Gilead Pharmasset Llc |
Synthesis of purine nucleosides
|
CA2762582A1
(en)
|
2009-05-27 |
2010-12-02 |
Merck Sharp & Dohme Corp. |
Hiv protease inhibitors
|
JP2012530069A
(ja)
|
2009-06-12 |
2012-11-29 |
ネクター セラピューティックス |
プロテアーゼ阻害剤、水溶性非ペプチドオリゴマーおよび親油性部分を含む共有結合体
|
DE102010004957A1
(de)
|
2010-01-14 |
2011-07-21 |
Universitätsklinikum Jena, 07743 |
Biologisch wirksame Moleküle zur Beeinflussung von Virus-, Bakterien-, Parasiten-infizierten Zellen und/oder Tumorzellen und Verfahren zu deren Anwendung
|
US20110223131A1
(en)
|
2010-02-24 |
2011-09-15 |
Gilead Sciences, Inc. |
Antiviral compounds
|
PT3290428T
(pt)
|
2010-03-31 |
2021-12-27 |
Gilead Pharmasset Llc |
Comprimido compreendendo 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2h)-il)¿4¿fluoro¿3¿hidroxi¿4¿metiltetrahidrofuran¿2¿il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropil cristalino
|
WO2012055031A1
(en)
|
2010-10-28 |
2012-05-03 |
Merck Canada Inc. |
Hiv protease inhibitors
|
EP2392926A1
(en)
|
2011-02-09 |
2011-12-07 |
Roche Diagnostics GmbH |
Urinary biomarkers in HIV infected subjects
|
US9133157B2
(en)
|
2011-10-26 |
2015-09-15 |
Merck Canada Inc. |
HIV protease inhibitors
|
WO2013105118A1
(en)
|
2012-01-10 |
2013-07-18 |
Council Of Scientific & Industrial Research |
A process for synthesis of syn azido epoxide and its use as intermediate the synthesis of amprenavir & saquinavir
|
BR112015005347A2
(pt)
|
2012-09-11 |
2017-08-08 |
Merck Sharp & Dohme Corp E Merck Canada Inc |
composto, composição farmacêutica, e, método para tratamento ou profilaxia de infecção por hiv ou para tratamento, profilaxia, ou atraso no início de aids
|
EP2912047B1
(en)
|
2012-10-29 |
2016-08-24 |
Cipla Limited |
Antiviral phosphonate analogues and process for preparation thereof
|
WO2015013835A1
(en)
|
2013-07-31 |
2015-02-05 |
Merck Sharp & Dohme Corp. |
Piperazine derivatives as hiv protease inhibitors
|
US9834526B2
(en)
|
2013-12-19 |
2017-12-05 |
Merck Sharp & Dohme Corp. |
HIV protease inhibitors
|
WO2015095265A1
(en)
|
2013-12-19 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Hiv protease inhibitors
|
EP3113780B1
(en)
|
2014-03-06 |
2019-08-14 |
Merck Sharp & Dohme Corp. |
Hiv protease inhibitors
|
EP3116862B1
(en)
|
2014-03-10 |
2019-04-17 |
Merck Sharp & Dohme Corp. |
Piperazine derivatives as hiv protease inhibitors
|
WO2016001907A1
(en)
|
2014-07-02 |
2016-01-07 |
Prendergast Patrick T |
Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
|
MX2017000026A
(es)
|
2014-07-11 |
2017-05-01 |
Gilead Sciences Inc |
Moduladores de receptores tipo toll para el tratamiento de virus de inmunodeficiencia humana (vih).
|
EP3212196A4
(en)
|
2014-10-29 |
2018-07-11 |
Wisconsin Alumni Research Foundation |
Boronic acid inhibitors of hiv protease
|
US20180263985A1
(en)
|
2015-09-15 |
2018-09-20 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors for the treatment of hiv
|
US20230218644A1
(en)
|
2020-04-16 |
2023-07-13 |
Som Innovation Biotech, S.A. |
Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
|